AVI Biopharma is reporting that their Morpholino drug for Duchenne muscular dystrophy is successfully triggering dose-dependent exon-skipping in the early low-dose phase of their systemic trial. Doses of 2 and 4 mg/Kg induced exon skipping and higher dosing is ongoing. http://finance.yahoo.com/news/Systemic-Treatment-With-iw-679670786.html?x=0&.v=1
Jon D. Moulton, Ph.D. Gene Tools, LLC www.gene-tools.com
Online Survey Software powered by Cvent
Board Rules | advertise | Privacy
Copyright © 2004-2012 Scientist Solutions, All Rights Reserved.Resources from NCBI used on this site.